open.michigan

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use.

Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

MUNIVERSITY OF MICHIGAN

CC BY NC SA

# Citation Key

for more information see: http://open.umich.edu/wiki/CitationPolicy

## Use + Share + Adapt

{ Content the copyright holder, author, or law permits you to use, share and adapt. }

- **PD-GOV** Public Domain – Government: Works that are produced by the U.S. Government. (USC 17 § 105)
- **PD-EXP** Public Domain – Expired: Works that are no longer protected due to an expired copyright term.
- **PD-SELF** Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.
- **ZERO** Creative Commons – Zero Waiver
- **BY** Creative Commons – Attribution License
- **BY-SA** Creative Commons – Attribution Share Alike License
- **BY-NC** Creative Commons – Attribution Noncommercial License
- **BY-NC-SA** Creative Commons – Attribution Noncommercial Share Alike License
- **GNU-FDL** GNU – Free Documentation License

## Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }

- **PD-INEL** Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (USC 17 § 102(b)) *laws in your jurisdiction may differ

{ Content Open.Michigan has used under a Fair Use determination. }

- **FAIR USE** Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (USC 17 § 107) *laws in your jurisdiction may differ

Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should do your own independent analysis to determine whether or not your use will be Fair.

# Classification of Immune Mediated Tissue Injury: Gell Coombs Classification

# Mechanisms of Immune-Mediated Disorders

(4- types)

J. Fantone: Host Defense

2/17/09

10:00-12:00am

Winter 2009

M

University of Michigan Medical School

# The four types of hypersensitivity reaction

![img-0.jpeg](img-0.jpeg)
type I

![img-1.jpeg](img-1.jpeg)
type II

![img-2.jpeg](img-2.jpeg)
type III

![img-3.jpeg](img-3.jpeg)
type IV

PD-INEL

Source Undetermined

# Type I Anaphylactic Type

- Prototype Disorders
- Allergic rhinnitis
- Allergic asthma
- Anaphylaxis (insect venom)

- Immune Mechanisms
- IgE-Mast cells
- Vascular permeability
- Eosinophils

# Type II, Cytotoxic Type

- Prototype Disorders
- Hemolytic reactions
- Goodpastures Syndrome
- Myasthenia Gravis
- Grave's Disease (hyperthyroidism)

- Immune Mechanisms
- IgG
- Complement
- Phagocytic cells
- ADCC

# Type III, Immune Complex Disease

- Prototype Disorders
- Post-streptococcal glomerulonephritis
- Vasculitis
- Polyarteritis nodosa
- Immune Mechanisms
- Ab-Ag reactions
- Complement
- Neutrophils
- Fibrin, hemorrhage

# Type IV, Cell-Mediated (Delayed) Hypersensitivity

- Prototype Disorders
- Poison Ivy
- Tuberculosis (granulomatous inflammation)
- Cytotoxic T-cell
- Dr. King’s lectures

- Immune Mechanisms
- T-lymphocytes
- Monocyte/macrophage

# Antibody-Mediated Cell and Tissue Injury: IgE Mediated Hypersensitivity Reactions

## Objectives:

To understand the pathophysiologic mechanisms associated with Type I anaphylactic hypersensitivity reactions

# Objectives (cont.)

- The role of IgE-mediated Mast cell degranulation in Type I reactions
- The primary effector mediators released during Mast cell stimulation
- The pathologic changes observed in tissues associated with anaphylactic hypersensitivity reactions
- The modulatory role of eosinophils in these reactions
- To correlate the effect of mediators on target organs with the clinical expression of anaphylactic reactions

# Clinical

- Type I reactions are usually the result of exposure to environmental allergens in genetically susceptible individuals
- 1/10 persons in USA affected to varying degrees
- Genetics not clearly defined, although there is a familial association
- Atopy: a genetic predisposition for developing IgE responses to many antigens
- Local or systemic symptoms

# Clinical (cont.)

- Most common form - allergic rhinnitis
- Also
- Certain types of asthma
- Atopic dermatitis (eczema)
- Certain gastrointestinal food allergies
- Allergens
- Pollens, molds, house dust mite, animal dander

![img-4.jpeg](img-4.jpeg)

PD-INEL

Source Undetermined

# Pathophysiology

Induction and effector mechanisms in Type I Hypersensitivity

![img-5.jpeg](img-5.jpeg)

PD-ENEL

Source Undetermined

![img-6.jpeg](img-6.jpeg)

# Degranulation and release of preformed mediators

![img-7.jpeg](img-7.jpeg)

Histamine Chemotactic factors Proteases

![img-8.jpeg](img-8.jpeg)

# De novo synthesis of mediators

![img-9.jpeg](img-9.jpeg)

Leukotrienes (C4, D4, E4) Prostaglandins Platelet activating factor Cytokines

![img-10.jpeg](img-10.jpeg)

Smooth muscle: bronchial, GI, vascular

Vascular endothelium

Secretory glands (e.g. mucous)

Eosinophils

I. Esatone

![img-11.jpeg](img-11.jpeg)
Resting mast cell

![img-12.jpeg](img-12.jpeg)
Activated mast cell

![img-13.jpeg](img-13.jpeg)
Resting mast cell shows granules containing serotonin and histamine

![img-14.jpeg](img-14.jpeg)
Multivalent antigen crosslinks bound IgE antibody causing release of granule contents

# Effects of Mediators in Anaphylaxis: Reversible Response

- Histamine - vascular permeability, vasodilation (post-capillary venule), smooth muscle contraction
- Chemotactic Factors
- Cytokines
- Lipid mediators

# Effects of Mediators in Anaphylaxis: Reversible Response (cont.)

- Lipid Mediators: Arachidonic acid metabolites
- Leukotriene C4, D4, E4 - smooth muscle contraction
- Prostaglandins - vasodilation

# Effects of Mediators in Anaphylaxis: Reversible Response (cont.)

- Lipid Mediators: PAF - platelet activating factor - low molecular weight lipid
- Acetylated glycerol ether phosphocholine (AGEPC)
- Activates phagocytic cells
- Smooth muscle contraction

# Role of Eosinophils in Anaphylaxis:

- Normal levels 2 to 3% circulating leukocytes
- Type 1 response: up to 10%+ circulating leukocytes
- Secretory products include:
- NADPH oxidase-derived oxidants
- Prostaglandins and Leukotrienes (LTC4)
- Major basic protein (MBP): cytotoxic
- Cytokines
- others

![img-0.jpeg](img-0.jpeg)

PO-2001

J. Fantone

# Pathologic Changes Associated with Anaphylactic Reactions: Reversible

- Symptoms depend on target organ: skin
- Gross: swelling, wheal and flare response
- early response: preformed mediators
- late response: synthesized mediators
- Light microscopic: edema, eosinophils
- Electron microscopic: edema, endothelial cell gaps

# Immediate and late skin reactions

late response (at 5 hours)

immediate response (at 20 minutes)

![img-1.jpeg](img-1.jpeg)

← 1:10
← 1:100
← 1:1000
← 1:10000

PD-TREE

Source Undetermined

# Pathologic Changes Associated with Anaphylactic Reactions: Reversible

- Mucous and serous glands
- Increased secretion
- Bronchial and GI smooth muscle
- Contraction

# Therapeutic Approaches

- Avoid antigen
- Mediator antagonists
- anti-histamines: receptor antagonist
- leukotriene inhibitors: lipase inhibitors, receptor antagonists
- functional: sympathetic stimulants
- Inhibit mast cell degranulation
- cromolyn
- Non-specific anti-inflammatory agents
- corticosteroids
- Immunotherapy ("allergy shots")

# Comparison of Skin Tests

|  Hypersensitivity Type | Time | Features  |
| --- | --- | --- |
|  Type 1 | Minutes | Wheal: edema
Flare: vasodilation
Eosinophils  |

# Diagnosis

- Skin test - most frequently used

![img-2.jpeg](img-2.jpeg)

PD-ENEL

Source Undetermined

# Serologic Tests: RAST - Radioallergosorbent Test - Specific IgE

![img-3.jpeg](img-3.jpeg)

+ Patient’s serum (Ab)

Bead with Ag

![img-4.jpeg](img-4.jpeg)

Anti-human IgE

IPO-TINEL

J. Fantone

# RIST - Radioimmunosorbent Test - Total IgE

![img-5.jpeg](img-5.jpeg)

RD-19181

J. Fantone

# Summary: Type I Reaction

- Antibody: IgE
- Effector Cells: Mast Cell &amp; Eosinophil
- Complement: No
- Reaction: Minutes

# Antibody-Mediated Cell and Tissue Injury

(Type II and Type III Reactions)

# The four types of hypersensitivity reaction

![img-6.jpeg](img-6.jpeg)
type I

![img-7.jpeg](img-7.jpeg)
type II
cell surface antigen

![img-8.jpeg](img-8.jpeg)
cytotoxic action
antibody
complement
complement
mediated lysis
target cell

![img-9.jpeg](img-9.jpeg)
type III
immune-complex deposition
complement
tissue basement membrane

![img-10.jpeg](img-10.jpeg)
type IV
antigens
inflammatory mediators
lymphokines
activated macrophage

#

PD-ENZL

Source Undetermined

# Pathophysiology

- Cytotoxic or Type II Reactions: Binding of Antibody (IgG or IgM) with cell membrane or tissue antigens
- Red blood cell membrane antigens - hemolytic anemias
- Platelet antigens - thrombocytopenia cell membrane - petechial hemorrhage
- Basement Membrane - Goodpasture’s syndrome
- Kidney - proteinuria
- Lung - hemorrhage

# Mechanisms

- Opsonin dependent phagocytosis
- Complement-dependent Ab lysis
- Antibody-dependent cell cytotoxicity

![img-11.jpeg](img-11.jpeg)

+ Ab

![img-12.jpeg](img-12.jpeg)

Fc dependent
Phagocytosis

+ complement
↓
LYSIS

![img-13.jpeg](img-13.jpeg)

+ NK-cells
↓
Fc-dependent
Cytotoxicity
(ADCC)

PD-INE
J. Fantone

# Rh Incompatibility in Newborn: Hemolytic Anemia

![img-14.jpeg](img-14.jpeg)

Preventative Therapy: Block sensitization by giving mother anti-D (Rho) Immunoglobulin within 72 hours after first birth or abortion

PD-INEL

J. Fantone

# Mechanisms (cont.)

- Antibody directed to tissue antigens: examples
- Goodpasture’s syndrome: antigen = basement membrane of kidney and lung
- Dermatitis Herpetiformis: antigen = epidermis basement membrane reticulin
- Bullous Pemphigoid: antigen = epidermis basement membrane
- Pemphigus vulgaris: antigen = epidermis keratinocyte membranes

# Goodpasture’s Syndrome

- Hemoptysis
- Pulmonary infiltrates
- Renal failure
- Anemia

# Pathology

- Circulating anit-GBM antibodies
- Lightmicroscopy: frequently neutrophils, hemorrhage
- Immunofluorescence: immunoglobulin and complement deposition; linear immunofluorescence
- Electron microscopy: no electron dense deposits

# Goodpastures Syndrome: Anti-GBM Disease

![img-0.jpeg](img-0.jpeg)

+ Complement → ▽ C3b deposition
↓ C3a + C5a
Proteases ↓
+ ← PMN recruitment
reactive oxygen
metabolites
↓
tissue injury

Lung: hemorrhage, hemoptysis, alveolar infiltrates
Kidney: proteinuria, hematuria, renal failure

# Goodpastures Syndrome: Anti-GBM Disease

![img-1.jpeg](img-1.jpeg)

cell phagocytosis

![img-2.jpeg](img-2.jpeg)

Dxygen radicals

Elastase

Collagenase

Acid hydrolases

![img-3.jpeg](img-3.jpeg)

PD-ENEL

J. Fantone

![img-4.jpeg](img-4.jpeg)

glomerulus

PO INFL

J. Fantone

![img-5.jpeg](img-5.jpeg)

POVINEI

Source Undetermined

# Damage mechanisms

## normal antimicrobial action

Fc receptor

![img-6.jpeg](img-6.jpeg)

C3 receptor

microbe

1. neutrophil

![img-7.jpeg](img-7.jpeg)

2. phagocytosis

![img-8.jpeg](img-8.jpeg)

3. lysosome fusion

## type II hypersensitivity reaction

![img-9.jpeg](img-9.jpeg)

4. neutrophil

![img-10.jpeg](img-10.jpeg)

5. 'frustrated phagocytosis'

![img-11.jpeg](img-11.jpeg)

6. extracellular enzyme release

P

PO-TREE

Source Undetermined

# Goodpastures Syndrome

![img-12.jpeg](img-12.jpeg)

- Linear antigen distribution
- Linear antibody + complement distribution
- Linear secondary anti-human antibody to IgG or complement containing a fluorescent marker

![img-13.jpeg](img-13.jpeg)

PD-INEL

Source Undetermined

Mechanisms (cont.)

- Antibody Binds to Cell Receptor (Type V Reactions)
- Hyperthyroidism (Grave’s Disease): Thyroid follicle cell - IgG antibody binds to thyroid stimulating hormone (TSH) receptor and stimulates cell
- Myasthenia Gravis: antibody to acetylcholine receptor at neuromuscular synapse antibody blocks neuromuscular transmission (decreased receptors) causing muscle weakness

# Antibody to Cell Receptors

![img-14.jpeg](img-14.jpeg)

A. STIMULATE CELL
B. BLOCK BINDING OF NATURAL LIGAND

52-INTL

J. Fantone

GRAVES DISEASE: Hyperthyroidism

![img-15.jpeg](img-15.jpeg)

J. Fantone

PO-1911

# The four types of hypersensitivity reaction

![img-16.jpeg](img-16.jpeg)
type I

![img-17.jpeg](img-17.jpeg)
type II

![img-18.jpeg](img-18.jpeg)
type III

![img-19.jpeg](img-19.jpeg)
type IV

PD-SHEL

Source Undetermined

![img-20.jpeg](img-20.jpeg)
Type III: Immune Complex Mediated Tissue Injury

PD-INE

J. Fantone

# Summary: Immune Complex Mediated Tissue Injury

Neutrophil influx

![img-21.jpeg](img-21.jpeg)

Phagocytosis of immune complexes

![img-22.jpeg](img-22.jpeg)

Oxygen metabolites O2-, H2O2 etc.

![img-23.jpeg](img-23.jpeg)

Lysosomal enzymes Proteases etc.

![img-24.jpeg](img-24.jpeg)

Tissue injury

PD-INE

J. Fantone

# Pathology of Immune Complex Injury

- Fibrinoid necrosis
- Hemorrhage
- Neutrophils
- Antibody + Complement deposition
- EM: Electron dense deposits
- Granular immunofluorescence

# Type III Hypersensitivity: Local I.C. Disease

![img-25.jpeg](img-25.jpeg)

PD-1NEL

Source Undetermined

# Immune Complex-Mediated Hypersensitivity (Type III) (cont.)

- Systemic immune complex disease

Foreign Ag injected I.V.

Immune response w/Ab production (IgM, IgG)

Circulating immune complexes formed

Tissue deposition w/complement fixation

Arteritis

Glomerulonephritis (w/proteinuria)

![img-26.jpeg](img-26.jpeg)

Foresign serum injection

Fever, vasculitis, arthritis, nephritis

Time (days)

Foresign serum injection

© PD-INEL

Source Undetermined

# Immune Complex-Mediated Hypersensitivity (Type III) (cont.)

- Pathology
- Light microscopy: neutrophils, hemorrhage, edema
- Electron microscopy: electron dense deposits
- Immunofluorescence: immunoglobulin and complement deposition, granular immunofluorescence pattern

# Immune Complex-Mediated Hypersensitivity (Type III) (cont.)

- Clinical - depends on target organ and/or site of immune complex deposition
- Synovium - rheumatoid arthritis
- Kidney - glomerulus
- Post-streptococcal glomerulonephritis
- Systemic lupus erythematosus
- Blood vessel walls - vasculitis
- Polyarteritis nodosa
- Early transplant rejection
- Lung - hypersensitivity pneumonitis

![img-0.jpeg](img-0.jpeg)

PO-SMEL

J. Fantone

![img-1.jpeg](img-1.jpeg)

#

J. Fantone

![img-2.jpeg](img-2.jpeg)

D

DOPHINSK

J. Fantone

![img-3.jpeg](img-3.jpeg)

PD-ENEL

J. Fantone

![img-4.jpeg](img-4.jpeg)

PD-INEL

Source Undetermined

# Immune Complex Disease (post-streptococcal glomerulonephritis)

![img-5.jpeg](img-5.jpeg)

- Irregular antigen distribution
- Irregular antibody + complement distribution
- Irregular secondary anti-human antibody to IgG or complement containing a fluorescent marker

PD-INE

J. Fantone

# Immune Complex-Mediated Hypersensitivity (Type III) (cont.)

- Diagnosis
- Skin tests for Type III reactions

- Therapy
- Elimination of antigen - as in transfusion reactions, hypersensitivity lung reactions to foreign antigens, and certain drug reactions
- Corticosteroid and immunosuppressive therapy (cytoxan, cylosporin)
- Plasmapheresis

# Summary: Type II/III Reaction

- Antibody: IgM &amp; IgG
- Effector Cells: Phagocytic
- Complement: Yes
- Reaction: 6-24 hours

# The four types of hypersensitivity reaction

![img-6.jpeg](img-6.jpeg)
type I

![img-7.jpeg](img-7.jpeg)
type II

![img-8.jpeg](img-8.jpeg)
type III

![img-9.jpeg](img-9.jpeg)
type IV

PD-INEL

Source Undetermined

# Type IV: Cell-Mediated Immune Reactions

## Objective

- To define the primary mechanisms involved in contact hypersensitivity and delayed type hypersensitivity reactions
- To review mechanisms of T-Cell mediated cytotoxicity (see Dr. King)

## Cell Components

- Mononuclear inflammatory cells: lymphocytes, monocytes/macrophages and antigen presenting cells

# Delayed hypersensitivity reactions

|  DTH type | characteristics  |   |   |   |
| --- | --- | --- | --- | --- |
|   |  reaction time | clinical appearance | histological appearance | antigen  |
|  contact | 48–72 hours | eczema | infiltration of lymphocytes and, later, macrophages, oedema of epidermis | epidermal: e.g. nickel, rubber, poison ivy usually a hapten  |
|  tuberculin | 48–72 hours | local hardening and swelling ± fever | infiltration of lymphocytes, monocytes, and macrophages | intradermal injection used diagnostically: tuberculin, mycobacterial and leishmanial antigens  |
|  granulomatous | 4 weeks | hardening e.g. in skin or lung | granuloma containing epithelioid cells, giant cells, and macrophages; fibrosis ± necrosis | persistent Ag or Ag–Ab complexes in macrophages; or 'non-immunological', e.g talcum powder  |

PD-ENEL

Source Undetermined

![img-10.jpeg](img-10.jpeg)

#

PD-INEL

Source Undetermined

![img-11.jpeg](img-11.jpeg)

PDF-DRCK

Source Undetermined

![img-12.jpeg](img-12.jpeg)

PD-INEL

Source Undetermined

![img-13.jpeg](img-13.jpeg)

PDF-DATE

Source Undetermined

![img-14.jpeg](img-14.jpeg)
The elicitation phase of contact hypersensitivity

#

PO-THEL

Source Undetermined

![img-15.jpeg](img-15.jpeg)

Q

PARTI

J. Fantone

![img-16.jpeg](img-16.jpeg)

PO-INEL

J. Fantone

![img-17.jpeg](img-17.jpeg)

PO-INEL

J. Fantone

# Granulomatous Inflammatory Reactions

![img-18.jpeg](img-18.jpeg)

PD-SNEL

J. Fantone

# Macrophage differentiation

![img-0.jpeg](img-0.jpeg)

PO-INEL

J. Fantone

# Summary: Type IV Reaction

- Antibody: No
- Effector Cells: T-lymphocytes, Monocyte/Macrophage
- Complement: No
- Reaction: 48-72 hours (skin test)

# Type IV: T-Cell Mediated Cytotoxicity

(see Dr. King’s presentation)

- Mechanisms
- CD8+ lymphocyte
- Antigen expressed with Class I MHC
- Interleukin-2 clonal expansion
- Cytotoxic effector cell
- Recognizes Ag+ class I MHC

# T-Cell Mediated Cytotoxicity

(cont.)

- Initiates programmed cell death (apoptosis)
- Perforins/cytolysins
- Proteolytic enzymes: granzymes
- FAS-induced apoptosis: CD8+ T cell: FAS ligand target cell: FAS receptor
- Cytokines
- Interferon γ
- Tumor Necrosis Factor α and β

# The four types of hypersensitivity reaction

![img-1.jpeg](img-1.jpeg)
type I

![img-2.jpeg](img-2.jpeg)
type II
cell surface antigen

![img-3.jpeg](img-3.jpeg)
cytotoxic action
antibody
complement
complement
mediated lysis
target cell

![img-4.jpeg](img-4.jpeg)
type III
immune-complex deposition
complement
blood vessel
tissue basement membrane

![img-5.jpeg](img-5.jpeg)
type IV
antigens
inflammatory mediators
lymphokines
activated macrophage

PD-3NEL

Source Undetermined

# Additional Source Information

for more information see: http://open.umich.edu/wiki/CitationPolicy

Slide 4: Source Undetermined
Slide 13: Source Undetermined
Slide 14: Source Undetermined
Slide 17: J. Fantone
Slide 22: J. Fantone
Slide 24: Source Undetermined
Slide 28: Source undetermined
Slide 29: J. Fantone
Slide 30: J. Fantone
Slide 33: Source Undetermined
Slide 36: J. Fantone
Slide 37: J. Fantone
Slide 41: J. Fantone
Slide 42: J. Fantone
Slide 43: J. Fantone
Slide 44: J. Fantone
Slide 45: Source Undetermined
Slide 46: Source Undetermined
Slide 47: J. Fantone
Slide 48: Source Undetermined
Slide 50: J. Fantone
Slide 51: J. Fantone
Slide 52: Source Undetermined
Slide 53: J. Fantone
Slide 54: J. Fantone
Slide 56: Source Undetermined
Slide 58: Source Undetermined
Slide 61: J. Fantone
Slide 62: J. Fantone
Slide 63: J. Fantone
Slide 64: J. Fantone
Slide 65: Source Undetermined
Slide 66: J. Fantone
Slide 69: Source Undetermined
Slide 71: Source Undetermined
Slide 72: Source Undetermined
Slide 73: Source Undetermined
Slide 74: Source Undetermined
Slide 75: Source Undetermined
Slide 76: Source Undetermined
Slide 77: J. Fantone
Slide 78: J. Fantone
Slide 79: J. Fantone
Slide 80: J. Fantone
Slide 81: J. Fantone
Slide 85: J. Fantone